Autopsy report · NCT02967380
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
Cause of deathSlow enrollment
“Insufficient Accrual”
Life of this trial
- Registered 3 years 9 months after it had already started.
- Ran for about 3 years 10 months before it stopped.
- 14 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Conditions
- Adult Anaplastic (Malignant) Meningioma; Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Neoplasm
- Interventions
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Gadobenate Dimeglumine; Gadobutrol; Gadopentetate Dimeglumine
- Participants
- 14
- Sites
- 1
- Countries
- United States
Trials that died the same way
- TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
“failure to accrue” - Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
“Insufficient accrual rate” - Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
“Inadequate accrual” - Osteoarthritis Shoulder Injection Study
“insufficient rate of accrual” - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
“unable to accrue”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.